Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy
- PMID: 30659849
- DOI: 10.1016/j.ophtha.2018.12.048
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy
Abstract
Purpose: To evaluate the long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy (CSC).
Design: Retrospective, longitudinal study.
Participants: A total of 133 participants (217 eyes) with chronic CSC.
Methods: A retrospective review of clinical and multimodal imaging data of patients with chronic CSC managed by 3 of the authors between May 1977 and March 2018. Multimodal imaging comprised color photography, fluorescein angiography, indocyanine green angiography, fundus autofluorescence (FAF), and OCT.
Main outcome measures: Best-corrected visual acuity (BCVA) at the final visit; change in BCVA between first visit and 1-, 5-, and 10-year follow-up visits; and causes of vision loss at final visit.
Results: Data from 6228 individual clinic visits were analyzed. Mean age of patients at the first visit was 60.7 years, and mean period of follow-up from first to last visit was 11.3 years. The cohort included 101 male patients (75.9%). At the final visit, 106 patients (79.7%) maintained driving-standard vision with BCVA of 20/40 or better in at least 1 eye, and 17 patients (12.8%) were legally blind with BCVA of 20/200 or worse in both eyes. Mean BCVA at first visit was not significantly different from mean BCVA at 1- or 5-year follow-up visits (both P ≥ 0.65) but was significantly better than the mean BCVA at the 10-year follow-up visit (P = 0.04). Seventy-nine percent of eyes with 20/40 or better vision at the first visit maintained the same level of vision at the 10-year follow-up visit. Ninety-two percent of eyes with 20/200 or worse vision at the first visit maintained the same level of vision at the 10-year follow-up visit. Cystoid macular degeneration, choroidal neovascularization (CNV), outer retinal disruption on OCT, and FAF changes were associated with poorer vision at the final visit (all P ≤ 0.001). Multivariable analysis revealed that greater age at first visit was associated with greater BCVA change at the 10-year follow-up visit (P = 0.001).
Conclusions: Chronic CSC can be a sight-threatening disease leading to legal blindness. Age at presentation and outer retinal changes on multimodal imaging were associated with long-term BCVA changes and may be predictors of long-term visual outcomes.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Comment in
-
A Backward Glance at Chronic Central Serous Chorioretinopathy.Ophthalmology. 2019 Apr;126(4):589-590. doi: 10.1016/j.ophtha.2018.11.012. Ophthalmology. 2019. PMID: 30910041 No abstract available.
Similar articles
-
Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy.Br J Ophthalmol. 2020 Nov;104(11):1561-1566. doi: 10.1136/bjophthalmol-2019-315302. Epub 2020 Feb 12. Br J Ophthalmol. 2020. PMID: 32051140
-
OCT Risk Factors for 3-Year Development of Macular Complications in Eyes With "Resolved" Chronic Central Serous Chorioretinopathy.Am J Ophthalmol. 2021 Mar;223:129-139. doi: 10.1016/j.ajo.2020.10.011. Epub 2020 Oct 22. Am J Ophthalmol. 2021. PMID: 33342759
-
Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.Eur J Ophthalmol. 2010 Sep-Oct;20(5):955-8. doi: 10.1177/112067211002000524. Eur J Ophthalmol. 2010. PMID: 20306440
-
Central serous chorioretinopathy: Current update on pathophysiology and multimodal imaging.Oman J Ophthalmol. 2018 May-Aug;11(2):103-112. doi: 10.4103/ojo.OJO_75_2017. Oman J Ophthalmol. 2018. PMID: 29930442 Free PMC article. Review.
-
Multimodal Imaging in Ocular Toxoplasmosis.Ocul Immunol Inflamm. 2020 Nov 16;28(8):1196-1204. doi: 10.1080/09273948.2020.1737142. Epub 2020 Mar 11. Ocul Immunol Inflamm. 2020. PMID: 32160073 Review.
Cited by
-
Focal Laser Photocoagulation for Central Serous Chorioretinopathy in Under-Represented Populations: A Retrospective Case Series.Case Rep Ophthalmol. 2022 Nov 28;13(3):991-998. doi: 10.1159/000527439. eCollection 2022 Sep-Dec. Case Rep Ophthalmol. 2022. PMID: 36605045 Free PMC article.
-
Two Cases of Chronic Central Serous Chorioretinopathy Successfully Treated with Systemic Interferon Alpha.Ocul Immunol Inflamm. 2024 Sep;32(7):1465-1474. doi: 10.1080/09273948.2023.2226206. Epub 2023 Jul 14. Ocul Immunol Inflamm. 2024. PMID: 37450492 Free PMC article.
-
Short Axial Length Is Related to Asymmetric Vortex Veins in Central Serous Chorioretinopathy.Ophthalmol Sci. 2021 Oct 26;1(4):100071. doi: 10.1016/j.xops.2021.100071. eCollection 2021 Dec. Ophthalmol Sci. 2021. PMID: 36246946 Free PMC article.
-
Significant Visual Impairment after Short-Lasting Central Serous Chorioretinopathy.Case Rep Ophthalmol. 2022 Sep 19;13(3):678-685. doi: 10.1159/000525924. eCollection 2022 Fall. Case Rep Ophthalmol. 2022. PMID: 36742018 Free PMC article.
-
Longitudinal follow-up and outcome analysis in central serous chorioretinopathy.Eye (Lond). 2023 Mar;37(4):732-738. doi: 10.1038/s41433-022-02044-z. Epub 2022 Apr 1. Eye (Lond). 2023. PMID: 35365777 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical